NIAID Advanced Technology STTR (NIAID-AT-STTR [R41/R42])

archived

Purpose. Add This funding opportunity announcement (FOA) encourages Small Business Technology Transfer Research (STTR) grant applications from small business concerns (SBCs) for advanced technology projects that require a longer award period and greater award amount than those routinely allowed under the SBIR program. For this FOA, "advanced technology" is defined as a clearly identified product or service that requires approval of the Food and Drug Administration (FDA) and is within the mission of NIAID. An example of a clearly identified product is a research project focused on a lead compound for an AIDS drug. A research project focused on developing an assay to identify lead compounds does not have a clearly identified product and would not be appropriate for this FOA. Only applications meeting the above advanced technology definition should be submitted in response to this FOA. Applications in response to this FOA should not contain human clinical trials. NIAID Policy currently only allows investigator initiated clinical trials to be submitted using the R34 mechanism. Information on this process can be found at the following site: http://funding.niaid.nih.gov/ncn/clinical/R34.htm. Mechanism of Support. This FOA will utilize the STTR (R41/R42) grant mechanisms for Phase I, Phase II, and and Fast-Track and runs in parallel with a FOA of identical scientific scope, PA-10-123, that encourages applications under the Small Business Innovation Research (SBIR) (R43/R44) grant mechanisms. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.

High